Flumazenil kinetics in the elderly.
In an open design, randomised, two-way cross-over study, a single 2 mg i.v. dose and a single 30 mg oral dose of flumazenil were each administered to a group of healthy young (n = 6) and elderly (n = 12) volunteers (male: female 2/1). Plasma samples were collected at intervals and intact drug was assayed. Both the i.v. and oral doses of flumazenil were very well tolerated by both age groups and no severe or unexpected adverse effects were observed. The main complaints were dizziness and headache, mainly after oral dosing, probably due to the higher Cmax and AUC following this route of administration. After 2 mg i.v. the disposition parameters in the two age groups (elderly/young) were very similar: volume of distribution (Vss): 0.88/0.90 l.kg-1; total body clearance (ClPL): 0.86/0.99 l.min-1; terminal elimination half-life (t1/2 beta): 1.02/0.91 h. After the 30 mg oral dose the mean Cmax of 87.6 ng.ml-1 (elderly) and 78.4 ng.ml-1 (young) were generally reached within 0.5 to 1 h. In 26% (elderly) and 23% (young), the absolute bioavailability of flumazenil was very similar. It is concluded that the absorption and disposition parameters of flumazenil were not significantly affected by aging.
Roncari
G
G
Department of Clinical Research, F. Hoffmann-La Roche, Basel, Switzerland.
Timm
U
U
Zell
M
M
Zumbrunnen
R
R
Weber
W
W
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000375:Aging / Q000378:metabolism; D001682:Biological Availability; D005260:Female; D005442:Flumazenil / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged
D005442:Flumazenil